Keybank National Association OH Sells 1,377 Shares of Haleon plc (NYSE:HLN)

Keybank National Association OH cut its stake in Haleon plc (NYSE:HLN) by 0.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 231,848 shares of the company’s stock after selling 1,377 shares during the quarter. Keybank National Association OH’s holdings in Haleon were worth $2,212,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of HLN. Sierra Ocean LLC purchased a new position in shares of Haleon during the fourth quarter valued at about $26,000. Versant Capital Management Inc boosted its position in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Haleon during the 4th quarter worth approximately $35,000. Toronto Dominion Bank raised its position in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after acquiring an additional 3,470 shares in the last quarter. Finally, Spire Wealth Management purchased a new position in shares of Haleon in the 4th quarter valued at approximately $39,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on HLN shares. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Finally, HSBC restated a “hold” rating on shares of Haleon in a report on Wednesday. Five research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Price Performance

Shares of NYSE:HLN opened at $10.39 on Friday. The business has a fifty day moving average price of $9.65 and a 200-day moving average price of $9.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market capitalization of $47.02 billion, a PE ratio of 30.55, a PEG ratio of 2.82 and a beta of 0.25. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80.

Haleon (NYSE:HLN) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, equities analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. Haleon’s dividend payout ratio is 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.